In An Incisional Model of Wound Healing, Genistein Aglycone Enhances Skin Recovery: A Comparison with Raloxifene and Estradiol in Ovariectomized Rats Is Presented

Abstract

Context and goal: Poor wound healing is commonly associated with estrogen depletion during menopause. Experiments on anti-aging cosmetic formulations using genistein have yielded intriguing findings about skin health. Here, we examined the effects of systemically administered the genistein aglycones in an incisional wound healing model in comparison to systemically administered estradiol and raloxifene. Method of experimentation: Rats were randomly divided into groups of 12 animals each six months after Ovariectomies (OVX) and given daily treatments of raloxifene hydrochloride (0.05 and 0.5 mg·kg-1s.c.), genistein aglycone (1 and 10 mg·kg-1s.c.) or 17-a-ethinyl estradiol (0.003 and 0.03 mg·kg-1s.c.) for a period of 12 weeks. Rats with OVX and sham OVX were not treated and served as controls. Then, an incisional wound healing technique was carried out 14 or 7 days before to the experiment’s conclusion and skin specimens were gathered to assess molecular, histological and functional measurements. Important Results: Compared to samples from sham OVX animals, samples from OVX rats seven and fourteen days after wounding shown a decrease in transforming growthfactor-b1, tissue transglutaminase 2 and vascular endothelial growth factor. Genistein, raloxifene and estradiol all considerably altered this decline, but the lowest dose of genistein had a stronger impact than the other two therapies. Furthermore, the best genistein dosage for enhancing wound tensile strength and skin healing was the lowest one. Inferences and conclusions: One potential alternative treatment for the control of skin wound healing is genistein aglycone.